More MS news articles for February 2001

Pathobiotek Reports Acceptance of Presentation at the 101st Annual Meeting For The American Society for Microbiology

Wednesday February 21, 10:00 am Eastern Time
Press Release
SOURCE: Pathobiotek Diagnostics Inc.

HOUSTON, Feb. 21 /PRNewswire/ -- Pathobiotek Diagnostics Inc. (OTC Bulletin Board: PBTK - news) a developer of products for the diagnosis and evaluation of treatment for multiple sclerosis (MS) and other immune disorders, Wednesday announced that an abstract has been accepted for the 101st Annual Meeting for the American Society for Microbiology in Orlando, Florida at the Orange County Convention Center.

Drs. Elena Jouravleva and Kathleen MacPhee, Scientists at Pathobiotek will deliver the Poster Presentation on May 24th, 2001. The presentation will address: quantitation of HBB1 directly from human blood through reverse transcriptase -- polymerase chain reaction (RT-PCR) analysis. HBB1 is the working name of the bacteria discovered by scientists at Pathobiotek. The preliminary data reported will provide a quantitative view of HBB1 controls in samples obtained from multiple sclerosis patients as compared to healthy controls.

This presentation is one in a series of publications and presentations planned to familiarize scientists and medical professionals with the ``HBB1 Technology'' and create interest among potential customers and strategic partners. Pathobiotek anticipates that an ever growing number of researchers will become involved in the pursuit of solutions associated with HBB1 and its many applications. There are several publications being planned by Pathobiotek and collaborating scientists at other institutions. Promulgation of this technology should help pave the route to increased revenue.

Safe Harbor Statement: Except for historical information contained herein, the matters set forth in this news release are forward-looking statements. Forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those identified in the company's filings with the Securities and Exchange Commission.

SOURCE: Pathobiotek Diagnostics Inc.